Understanding how HIV affects the intestinal barrier
Molecular mechanisms underlying HIV related intestinal epithelial barrier dysfunction
This study is looking at how HIV affects the gut and can cause ongoing health issues, with the goal of finding new ways to help people living with HIV stay healthier, even if they are on treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10876444 on NIH RePORTER |
What this research studies
This research investigates the ways in which HIV infection disrupts the function of the intestinal barrier, leading to various health complications. It focuses on how microbial translocation across a damaged epithelial barrier contributes to chronic inflammation and immune activation in individuals living with HIV. By examining the molecular mechanisms involved, the research aims to identify potential therapeutic targets to prevent inflammation-related diseases that can arise even in patients receiving antiretroviral therapy. The study is conducted by a team of experts in HIV biology and intestinal health, utilizing preliminary data to guide their investigations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV, particularly those experiencing complications related to intestinal barrier dysfunction.
Not a fit: Patients who are not living with HIV or those whose intestinal barrier function is not affected by HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent chronic inflammation and associated health issues in people living with HIV.
How similar studies have performed: Previous research has shown promising results in understanding the relationship between HIV and intestinal health, indicating that this approach has potential for significant advancements.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Parkos, Charles a — University of Michigan at Ann Arbor
- Study coordinator: Parkos, Charles a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.